Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation

  • Maria Vinci1,

    Affiliated with

    • Sharon Gowan1,

      Affiliated with

      • Frances Boxall1,

        Affiliated with

        • Lisa Patterson1,

          Affiliated with

          • Miriam Zimmermann1,

            Affiliated with

            • William Court1,

              Affiliated with

              • Cara Lomas1,

                Affiliated with

                • Marta Mendiola2,

                  Affiliated with

                  • David Hardisson3 and

                    Affiliated with

                    • Suzanne A Eccles1Email author

                      Affiliated with

                      BMC Biology201210:29

                      DOI: 10.1186/1741-7007-10-29

                      Received: 24 January 2012

                      Accepted: 22 March 2012

                      Published: 22 March 2012

                      Abstract

                      Background

                      There is overwhelming evidence that in vitro three-dimensional tumor cell cultures more accurately reflect the complex in vivo microenvironment than simple two-dimensional cell monolayers, not least with respect to gene expression profiles, signaling pathway activity and drug sensitivity. However, most currently available three-dimensional techniques are time consuming and/or lack reproducibility; thus standardized and rapid protocols are urgently needed.

                      Results

                      To address this requirement, we have developed a versatile toolkit of reproducible three-dimensional tumor spheroid models for dynamic, automated, quantitative imaging and analysis that are compatible with routine high-throughput preclinical studies. Not only do these microplate methods measure three-dimensional tumor growth, but they have also been significantly enhanced to facilitate a range of functional assays exemplifying additional key hallmarks of cancer, namely cell motility and matrix invasion. Moreover, mutual tissue invasion and angiogenesis is accommodated by coculturing tumor spheroids with murine embryoid bodies within which angiogenic differentiation occurs. Highly malignant human tumor cells were selected to exemplify therapeutic effects of three specific molecularly-targeted agents: PI-103 (phosphatidylinositol-3-kinase (PI3K)-mammalian target of rapamycin (mTOR) inhibitor), 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) (heat shock protein 90 (HSP90) inhibitor) and CCT130234 (in-house phospholipase C (PLC)γ inhibitor). Fully automated analysis using a Celigo cytometer was validated for tumor spheroid growth and invasion against standard image analysis techniques, with excellent reproducibility and significantly increased throughput. In addition, we discovered key differential sensitivities to targeted agents between two-dimensional and three-dimensional cultures, and also demonstrated enhanced potency of some agents against cell migration/invasion compared with proliferation, suggesting their preferential utility in metastatic disease.

                      Conclusions

                      We have established and validated a suite of highly reproducible tumor microplate three-dimensional functional assays to enhance the biological relevance of early preclinical cancer studies. We believe these assays will increase the translational predictive value of in vitro drug evaluation studies and reduce the need for in vivo studies by more effective triaging of compounds.

                      Keywords

                      3D angiogenesis drug response high throughput invasion migration tumor spheroids

                      Background

                      The preclinical validation process in cancer drug discovery generally comprises a series of primary biochemical and cell-based assays, followed by evaluation in animal tumor models. However, there is a high rate of attrition and fewer than 10% of candidates identified by high-throughput (HT) screening become licensed drugs [1]. Standard two-dimensional cell cultures for testing effects of anticancer agents are simple and convenient, but present significant limitations in reproducing the complexity and pathophysiology of in vivo tumor tissue [28].

                      Three-dimensional culture systems are of increasing interest in cancer research since tissue architecture and the extracellular matrix (ECM) significantly influence tumor cell responses to microenvironmental signals. For example, inhibition of β1-integrin on breast tumor cells reverted their morphological and functional features to a normal epithelial phenotype, but only in three dimensions [9]. This and many other studies have highlighted significant differences between two-dimensional and three-dimensional cultures, with the latter reflecting better the in vivo tumor microenvironment in terms of cellular heterogeneity, nutrient and oxygen gradients, cell-cell interactions, matrix deposition and gene expression profiles [5, 6, 811]. To model solid tumors more effectively, several three-dimensional culture systems have been established: whole perfused organs, tissue explants, scaffold/microcarrier-based cultures, hollow-fiber bioreactors, organotypic cultures (multicellular spheroids and cellular multilayers) and gel/matrix-based cultures [3, 4, 1215]. Of these, the multicellular tumor spheroid model is the best characterized and most widely used.

                      Tumor spheroids are heterogeneous cellular aggregates that, when greater than 500 μm diameter, are frequently characterized by hypoxic regions and necrotic centers [16, 17]. Three-dimensional spheroids are therefore considered valid models to recapitulate features of tumor microregions, intervascular domains or micrometastases [10, 12]. Sutherland et al. first applied this technique in cancer research [18]. Since then, several methods have been used to generate tumor spheroids: spontaneous aggregation [19, 20], spinner flasks [21], rotary cell culture systems [3, 22], poly-2-hydroxyethyl methacrylate (poly-Hema)-coated plates [23, 24], hanging drops [25], liquid overlay on agar [2628], low binding plates [29, 30], gel/matrix-based culture [31], polymeric scaffolds [11] or micropatterned plates [32, 33].

                      Each method has advantages and limitations [3, 13] but simple, standardized and rapid protocols appropriate for routine preclinical drug development studies within academic or pharmaceutical labs are lacking. Furthermore, there is an appreciation that the next generation of anticancer drugs will need to address aspects of the malignant phenotype beyond cell proliferation if we are to effectively address disseminated disease. We have therefore developed a complete suite of in vitro three-dimensional spheroid-based assays for measuring tumor growth, migration, invasion and tumor angiogenesis that, combined with new technologies of automated imaging and analysis, demonstrate applicability in relatively high-throughput formats.

                      We initially screened and classified a diverse collection of human tumor cell lines for their ability to form spheroids. For more detailed assay exemplification, selected lines representing highly malignant human tumors and characterized by an optimal three-dimensional structure were used. The following report is divided into two sections: a description of the establishment of the suite of three-dimensional spheroid growth and functional assays, and an exemplification of the utility of the assays to measure inhibitory effects of molecularly targeted agents. Inhibitors of heat shock protein 90 (HSP90) chaperone (17-N-allylamino-17-demethoxygeldanamycin (17-AAG)), phosphatidylinositol-3-kinase (PI3K)-mammalian target of rapamycin (mTOR) (PI-103) and phospholipase C (PLC)γ (CCT130234), representing a variety of validated targets in tumor growth, invasion and angiogenesis [3437], were selected for evaluation. We believe that these assays will contribute to increased utility and predictive value of preclinical drug discovery studies.

                      Results

                      Establishment of three-dimensional spheroid-based assays

                      Rapid generation of reproducibly sized tumor spheroids and automated growth kinetic analyses

                      To deploy three-dimensional cultures in cancer drug discovery and target validation, we established a standardized microplate method with the following desirable characteristics: (i) 96-well suspension culture; (ii) a single spheroid/well, centered for ease of optical imaging; (iii) high reproducibility; (iv) simple harvesting for further analysis; (v) fully automated imaging and quantitative analysis.

                      We used ultra-low attachment (ULA) 96-well round-bottomed plates that, in contrast to standard methods, do not require coating to prevent cell adhesion. Tumor cell suspensions formed a three-dimensional structure within 24 to 48 h. The well shape promotes the formation of single, centrally located spheroids of reproducible size (Figure 1a). Optimal seeding densities were established such that tumor spheroids for every cell line tested (regardless of their proliferative potential and cell cycle time) fell within a size range of 300 to 500 μm in diameter on day 4, considered appropriate for initiating experimental studies. Cultures were maintained by replacing 50% of the medium on days 4, 7, 10 and 12.
                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig1_HTML.jpg
                      Figure 1

                      High throughput (HT) standardized method for generation, imaging and analysis of tumor spheroids. (a) Ultra-low attachment (ULA) 96-well round-bottomed plates were used to generate suspension cultures of reproducibly sized, single spheroids in each well. (b) Fully automated imaging and analysis was carried out on a Celigo cytometer using the Colony Counting Embryoid Body application with 1/16 field of view/well. A screen print shows reproducibly sized U-87 MG spheroids across the plate and detail of the segmentation analysis around the spheroid. Scale bar: 500 μm. (c) U-87 MG tumor spheroid growth curve. Values are means ± SD (n = 6). Representative images obtained on Celigo for each timepoint are shown. Scale bar 500 μm. (d) Frequency plots of 4-day U-87 MG spheroid volume (μm3 × 107) across a plate containing 60 spheroids.

                      For rapid, routine imaging and analysis of tumor spheroids, we utilized a Celigo™ cytometer (Cyntellect Inc, San Diego, CA, USA; http://​www.​cyntellect.​com/​content/​products/​celigo/​index.​html) (Figure 1b), which is a benchtop in situ cellular analysis system providing high quality, full or partial images of wells using brightfield or fluorescent illumination. Images were acquired and analyzed using the Colony Counting Embryoid Body (EB) application that identifies and counts individual three-dimensional structures (EBs or spheroids) and small clusters of cells. With our centrally located spheroids and by selecting 1/16 field of view/well (Figure 1b) the Celigo cytometer scans a ULA 96-well plate in 8 minutes, allowing fast, automated multiparametric analysis including measurements of spheroid diameter, perimeter and area. This application allows the generation of image segmentation around the spheroid, as shown in Figure 1b. Images are acquired at intervals and growth curves are rapidly and easily generated, showing linear volume increases up to 14 days following cell seeding. An example using U-87 MG glioblastoma is shown in Figure 1c. Small standard deviations demonstrate the reproducibility and robustness of the method.

                      We tested 40 tumor cell lines in total (Table 1) and classified spheroids according to their morphology, extending the original Ivascu classification [23] as follows: tight spheroids (for example, SF188 glioblastoma): tight, spherical and regular; compact aggregates (for example, MDA-MB-231 breast carcinoma): acceptable for three-dimensional studies but less regular; loose aggregates (for example, IGROV-1 ovarian carcinoma): irregular, friable aggregates (Table 1 and Additional file 1). The three-dimensional structure of compact and loose spheroids can be improved by the addition of Matrigel™ (BD Biosciences, Oxford, England) at the time of initiation, extending the range of tumor cells suitable for further study (Additional file 1).
                      Table 1

                      Tumor cell lines

                      Cell line

                      Tumor type

                      Three-dimensional morphology

                      Supplier

                      Medium

                      U-87 MG

                      GBM (adult)

                      T

                      ATCC

                      1

                      A172

                      GBM (adult)

                      T

                      ATCC

                      1

                      SF126

                      GBM (adult)

                      T

                      JCRB

                      1

                      LN-229

                      GBM (adult)

                      T

                      ATCC

                      1

                      SF268

                      GBM (adult)

                      C

                      NCI repository

                      1

                      SF188

                      GBM (pediatric)

                      T

                      Bax, 2009 [56]

                      2

                      KNS42

                      GBM (pediatric)

                      T

                      Bax, 2009 [56]

                      2

                      RES186

                      Astrocytoma (pediatric)

                      T

                      Bax, 2009 [56]

                      2

                      RES259

                      Astrocytoma (pediatric)

                      T

                      Bax, 2009 [56]

                      2

                      UW479

                      Astrocytoma (pediatric)

                      L

                      Bax, 2009 [56]

                      2

                      WT-CLS1

                      Wilm's kidney

                      T

                      CRUK Cell Line Services

                      1

                      WiT49

                      Wilm's kidney

                      T

                      Dr H Yeger, Hospital for Sick Children, Toronto

                      1

                      IMR-32

                      Neuroblastoma

                      T

                      ATCC

                      1

                      SH-SY5Y

                      Neuroblastoma

                      C

                      Dr L Chesler, ICR

                      3

                      KELLY

                      Neuroblastoma

                      C

                      Dr L Chesler, ICR

                      3

                      SHEP

                      Neuroblastoma

                      T

                      Dr L Chesler, ICR

                      3

                      U-2 0S

                      Osteosarcoma

                      C

                      ATCC

                      1

                      Detroit 562

                      SCC (pharynx)

                      T

                      ATCC

                      1

                      CAL 27

                      SCC (tongue)

                      T

                      ATCC

                      1

                      PECA/CA-PJ34

                      SCC (basaloid)

                      T

                      ECACC

                      4

                      PE/CA-PJ41a

                      SCC (oral)

                      C

                      ECACC

                      4

                      SIHN-011A

                      SCC (tongue)

                      C

                      O-charoenrat, 2001 [57]

                      1

                      LICR-LON-HN4

                      SCC (larynx)

                      T

                      Easty, 1981 [58]

                      1

                      SK-Mel-5

                      Melanoma

                      L

                      ATCC

                      1

                      NCI-H23

                      Lung

                      C

                      ATCC

                      3

                      MDA-MB-231a

                      Breast

                      C

                      ATCC

                      1

                      MCF-7

                      Breast

                      C

                      ATCC

                      1

                      DLD-1

                      Colon

                      T

                      ATCC

                      1

                      HCT 116

                      Colon

                      T

                      ATCC

                      1

                      RKOa

                      Colon

                      L

                      ATCC

                      1

                      HT-29

                      Colon

                      T

                      ATCC

                      1

                      SW620a

                      Colon

                      L

                      ATCC

                      1

                      PC-3a

                      Prostate

                      L

                      ATCC

                      3

                      A2780

                      Ovarian

                      L

                      ECACC

                      3

                      IGROV-1a

                      Ovarian

                      L

                      CRUK Cell Line Services

                      3

                      SK-OV-3a

                      Ovarian

                      L

                      ATCC

                      3

                      PANC-1a

                      Pancreatic

                      C

                      ATCC

                      1

                      MIA PaCa-2

                      Pancreatic

                      L

                      ATCC

                      1

                      Hep G2

                      Hepatocellular

                      C

                      ATCC

                      5

                      Hep 3B

                      Hepatocellular

                      C

                      ATCC

                      5

                      aCell lines in which three-dimensional structure is improved by addition of Matrigel at spheroid initiation.

                      Medium: 1 = DMEM; 2 = DMEM:F12; 3 = RPMI; 4 = Iscove's Modified Dulbecco's Medium; 5 = Eagle's Minimum Essential Medium.

                      ATCC = American Type Culture Collection; C = compact aggregate; ECACC = European Collection of Cell Cultures; GBM = glioblastoma; JCRB = Japanese Collection of Research Bioresources; L = loose aggregate; SCC = squamous cell carcinoma; T = tight spheroid

                      To demonstrate the reproducibility in spheroid size, the coefficient of variation (CV) of spheroid volumes on day 4 was determined for selected highly malignant tumor cell lines that form tight spheroids. The intraplate CV was 5.53% to 7.15% for U-87 MG (adult glioblastoma), 4.97% to 10.57% for KNS42 (pediatric glioblastoma) and 7.59% to 10.59% for LICR-LON-HN4 (laryngeal squamous cell carcinoma). The interplate CV gave values of 17.88% for U-87 MG, 11.21% for KNS42 and 10.75% for LICR-LON-HN4 (n = 3, tested over three different batches of plates). Furthermore the spheroid volume distribution follows a Gaussian distribution (U-87 MG, Figure 1d). Similar results were obtained for other cell lines such as KNS42 and LICR-LON-HN4 (data not shown).

                      In order to compare our system to a standard conventional method, U-87 MG spheroids were initiated and cultured in parallel on agar-coated 96-well flat-bottomed plates [26] and in ULA 96-well round-bottomed plates (Figure 2). The agar-coated plates, unlike the ULA plates, proved unsuitable for automated image analysis on the Celigo cytometer (probably due to variations in the thickness of agar in each well). Thus, images were obtained at intervals using an Olympus IX 70 (Olympus Microscopy, Southend-on-SeaEssex, UK) inverted microscope. Analysis was carried out using Image-Pro Plus Analyzer software (Media Cybernetics, Inc., Bethesda, MD, USA; http://​www.​mediacy.​com/​index.​aspx?​page=​IPP). Reproducibly sized spheroids (a single spheroid/well) were obtained in each system, with ULA spheroids growing to slightly larger sizes than the agar-based spheroids but both growth curves reached a plateau at around day 14 (Figure 2a).
                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig2_HTML.jpg
                      Figure 2

                      Tumor spheroid growth: ultra-low attachment (ULA) 96-well round-bottomed plates vs agar-coated 96-well flat-bottomed plates. (a) ULA 96-well round-bottomed plates and agar-coated 96-well flat-bottomed plates were used to generate U-87 MG spheroids (a single spheroid per well). Starting from day 4 post initiation, images were obtained at intervals using an inverted microscope. Analysis was carried out using Image-Pro Analyzer software and growth curves were obtained. Values are means ± SD (n = 16 spheroids/timepoint; a representative result of two independent experiments is shown). (b) Representative images of U-87 MG spheroids grown on ULA plates or on agar-coated plates at the indicated timepoints. Scale bar: 100 μm.

                      Spheroids grown on ULA plates showed a more compact structure than those on agar-coated plates (Figures 2b, 3a, b and Additional file 2a). In both cases, (suspension and agar plated) larger U-87 MG spheroids develop a gradient of proliferation as measured by Ki-67 staining [10] and a more intense glucose transporter 1 (GLUT-1) staining (Figure 3a, b) that correlates with tumor hypoxia [38]. Central necrosis was not evident in U-87 MG spheroids over this observation period although was seen in HCT 116 spheroids (data not shown). Thus, overall our system compares closely with conventionally-generated spheroids, but with the advantage that automated analysis and retrieval of spheroids for molecular analysis is more easily achieved with suspension cultures in ULA plates. U-87 MG spheroids were also grown on poly-Hema-coated 24-well plates and in a Rotary Cell Culture System (RCCS; Synthecon, El Rio Houston, TX, USA; http://​www.​synthecon.​com/​) (Additional file 2c) but multiple non-reproducibly sized spheroids were formed and hence these methods were not pursued further.
                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig3_HTML.jpg
                      Figure 3

                      Comparison of U-87 MG spheroids grown on ultra-low attachment (ULA) plates or agar: immunostaining. Hematoxylin and eosin (H&E), glucose transporter 1 (GLUT-1) or Ki67 antibody staining of sections of U-87 MG spheroids grown for 4, 7 and 14 days on (a) ULA 96-well round-bottomed plates or (b) agar-coated 96-well flat-bottomed plates. Spheroids on (a) ULA plates show a tighter structure than spheroids grown on (b) agar, across all timepoints. H&E staining is homogeneous, while there was a gradient of proliferation (Ki67) in larger spheroids (day 14). A more intense staining of GLUT-1 was observed concomitantly with the age of the spheroids, irrespective of the means of generation (a, b). Scale bar 100: μm.

                      Three-dimensional tumor spheroid functional assays

                      Another major advantage of our approach is its convenient extension to additional three-dimensional functional assays to address important cellular processes in tumor progression: (i) migration on extracellular matrix proteins (ECM), (ii) invasion into Matrigel and (iii) simultaneous tissue invasion/angiogenesis (by coculture with EBs) (Figures 4 and 5).
                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig4_HTML.jpg
                      Figure 4

                      Three-dimensional tumor spheroid-based functional assays: migration and invasion. (a) Tumor spheroid-based migration is illustrated in a cartoon: a single day 4 tumor spheroid was transferred to each well of extracellular matrix (ECM)-coated 96-well flat-bottomed plate using a multichannel pipette. (b) Representative brightfield images of U-87 MG and KNS42 cell migration (48 h) are shown. (c) Tumor spheroid invasion into Matrigel is illustrated in a cartoon: a single tumor spheroid per well was embedded in Matrigel. (d) Representative images of a typical U-87 MG 'starburst' invasion pattern obtained with a Celigo cytometer. The Cell Counting Confluence application (1/16 field of view/well) produces a segmentation analysis that identifies the area occupied by invading cells. (e) Representative images obtained using a conventional inverted microscope show the U-87 MG invasion at low magnification and details of invadopodia advancing into the matrix shown at higher magnification. Scale bar: 100 μm.

                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig5_HTML.jpg
                      Figure 5

                      Mouse embryonic stem cell (mESC) differentiation into embryoid bodies (EBs) and confrontation culture with tumor spheroids. (a) R1 mES cells grown as colonies on feeder layers of mouse embryonic fibroblasts (MEFs) in the presence of leukemia inhibitory factor (LIF). (b) Suspension growth of mESCs on ultra-low attachment (ULA) 96-well round-bottomed plates allows spontaneous differentiation into EBs. Representative images of EBs are shown. Scale bar: 500 μm. (c) EB growth curve, determined by automated imaging analysis on a Celigo cytometer, (n = 12 EBs/timepoint). Values are mean ± SD. (d) CD34 staining of day 12 EBs shows endothelial differentiation (brown staining). Scale bar: 100 μm (left) or 50 μm (right). (e) Confrontation culture of green fluorescent protein (GFP)-transduced U-87 MG tumor spheroid (TS) and EB is represented in a cartoon on the left: a single TS and EB are cocultured in each well of a ULA 96-well round-bottomed plate. Representative images are shown at t0 and 55 h. Images were obtained on a Celigo cytometer. Scale bar: 500 μm. (f) Selected frames of a timelapse study show mutual invasion and coalescence of the two organoids. Images were obtained on an inverted microscope. Scale bar: 500 μm.

                      Migration on matrix protein

                      We utilized a tumor spheroid-based migration assay that resembles tumor cell dissemination from a solid microtumor or micrometastasis in terms of engagement of host stromal matrix proteins with characteristics that differ from isolated cells [3941]. The same type of assay has been used previously in a lower throughput format and with more time-consuming methods for generation of tumor spheroids [4244]. We successfully modified the assay for HT format by rapidly transferring tumor spheroids generated in ULA round-bottomed plates into gelatin-coated flat-bottomed 96-well plates (a single spheroid/well) using a multichannel pipette (Figure 4a). Within a few hours, tumor cells disseminate from the spheroid over the coated surface [44] and migration is recorded at intervals up to 72 h. Images can be obtained using an inverted microscope and analysis performed using Image-Pro Analyzer software by manually recording the leading edge of the migrating cells, which enables the software to calculate the area covered. This assay also provides valuable qualitative information on different cell migration patterns (Figure 4b). For example, U-87 MG cells show rapid, single cell dispersal resembling typical amoeboid migration [45, 46]. In contrast, KNS42 cells move slowly and collectively in a radial pattern, reflecting a more mesenchymal phenotype [45, 46] (Additional files 3 and 4).

                      Three-dimensional invasion into Matrigel

                      To measure three-dimensional tumor invasion (Figure 4c), spheroids are initiated as described above and on day 4 Matrigel is added to the wells. This provides a semisolid gel-like matrix into which cells extend invadopodia [47, 48]; these processes contribute to cell movement and also matrix degradation via localized proteolysis [47]. Within a few hours, the invadopodia are apparent and invasion is monitored at intervals over 72 h. Image analysis is performed on a Celigo cytometer by using the Cell Counting Confluence application, which determines the area occupied by individual cells or cell clusters, identified by image segmentation around the invading cells (Figure 4d). The central location of each spheroid allows rapid and automated image analysis and by selecting 1/16 field of view per well the scan is completed within 10 minutes/plate. Alternatively, images can be obtained using an inverted microscope and analysis is performed as described for the migration. Microscopy additionally provides detailed images of the invading cell protrusions as shown in Figure 4e.

                      Tissue invasion and angiogenesis

                      The angiogenic switch is a critical step in tumor progression [49]. We modified a confrontation culture assay of spheroids and EBs [21] to mimic simultaneous tissue invasion and tumor angiogenesis in vitro. With their complex cellular heterogeneity, including differentiated endothelial cells, EBs represent a true tissue environment. The method is a simple three-step procedure: (1) culture of mouse embryonic stem cells (mESCs) (Figure 5a); (2) differentiation of mESCs into EBs (Figure 5b, c); (3) coculture of spheroids and EBs (Figure 5d, e). To optimize the assay for future HT target validation and/or drug evaluation studies, EBs were grown in ULA 96-well round-bottomed plates rather than Petri dishes [50] or spinner flasks [21], increasing EB reproducibility and significantly reducing the time needed for assay set-up. Fully automated cytometer image analysis shows linear growth curves with increased variability only during later stages of maturation (Figure 5b). Consistent with previous reports [21, 50], we demonstrated endothelial differentiation by CD34 staining (Figure 5d).

                      Our confrontation culture is a significant enhancement of previous assays, since day 4 tumor spheroids are transferred directly into wells containing day 5 EBs (when endothelial cell differentiation begins [21]) and the system allows real-time analysis of subsequent interactions. Representative images from the Celigo cytometer show two distinct bodies at confrontation, with the U-87 MG spheroid identified by green fluorescent protein (GFP) fluorescence. The mutual integration process is complete within 50 to 60 h, as shown in the merged brightfield and fluorescent images (Figure 5e). Confrontation cultures can also be imaged by microscopy, allowing timelapse studies (Figure 5f and Additional file 5). Treatment with 17-AAG was shown to inhibit U-87 MG EB tissue invasion (Additional file 6). Tumor-stimulated angiogenesis is illustrated by immunohistochemical staining of EB-derived endothelial cells within tumor spheroids (Additional file 7).

                      Together, these assays provide a suite of novel, complementary functional assays with immediate relevance to cancer progression and enabling rapid evaluation of new therapeutic agents, as exemplified below.

                      Exemplification of the methods for evaluation of anticancer agents

                      Evaluation of effects of signaling inhibitors on cell viability in three-dimensional vs two-dimensional cultures

                      In order to evaluate responsiveness in our suite of tumor spheroid assays, we first compared the sensitivity of cells in three-dimensional vs two-dimensional cultures to selected compounds using the CellTiter Glo cell viability assay which is quick, easy and reproducible. This was validated in pilot studies that determined optimum incubation time of the reagents, and showed good correlation between spheroid size and luminescent emission as well as spheroid size and the number of viable cells per spheroid (Additional file 8).

                      MDA-MB-231, U-87 MG, KNS42 and LICR-LON-HN4 cells were treated with 17-AAG (HSP90 chaperone inhibitor), PI-103 (PI3 kinase/mTOR inhibitor) or CCT130234 (PLCγ inhibitor) in two-dimensional and three-dimensional cultures, and concentrations inhibiting cell viability by 50% (GI50) were determined after 72 h. Tumor cells were generally less sensitive to compounds in three-dimensional than in two-dimensional cultures (Table 2 and Additional file 9). MDA-MB-231 P (parental variant) cells treated with 17-AAG showed a clear shift of the cell survival curve, resulting in a higher GI50 in three dimensions (Additional file 10a). This could reflect reduced compound access or pathophysiological differences in the response of hypoxic or more slowly cycling cells under these conditions (as in solid tumors in vivo [51]). This was not the case with CCT130234 in three dimensions (Additional file 10b). Furthermore, both U-87 MG and KNS42 were more sensitive in three dimensions to PI-103 (Table 2 and Additional file 9) confirming previous reports of increased sensitivity to PI3 kinase inhibitors in three dimensions [34]. This highlights the importance of accurately evaluating drug responses under appropriate conditions in vitro in order to avoid overestimating or underestimating the effect of compounds prior to in vivo studies.
                      Table 2

                      Concentration inhibiting cell viability by 50% (GI50) values for selected tumor cell lines treated with 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), PI-103 or CCT130234

                      Inhibitor (μM)

                      Cell line

                      Two-dimensional

                      Three-dimensional

                      17-AAG:

                      U-87 MG

                      0.43 ± 0.13

                      0.82 ± 0.16

                       

                      KNS42

                      18.02 ± 6.42

                      81.43 ± 1.60

                       

                      MDA-MB-231 P

                      2.47 ± 0.83

                      2.33 ± 0.33

                       

                      MDA-MB-231 M

                      0.75 ± 0.10

                      6.19 ± 0.50

                       

                      LICR-LON-HN4

                      0.07 ± 0.06

                      0.38 ± 0.11

                      PI-103:

                      U-87 MG

                      0.49 ± 0.13

                      0.16 ± 0.03

                       

                      KNS42

                      2.15 ± 1.20

                      0.72 ± 0.34

                       

                      MDA-MB-231 P

                      2.39 ± 0.69

                      > 100

                      CCT130234:

                      U-87 MG

                      9.10 ± 1.13

                      16.40 ± 0.14

                       

                      MDA-MB-231 P

                      11.5 ± 3.32

                      8.50 ± 0.62

                      Cells cultured in two dimensions and three dimensions were treated with compounds for 72 h. A CellTiter Glo® viability assay was performed and GI50 values were obtained. Values are means ± SD of the studies reported in Additional file 10 (apart from MDA-MB-231 P that when treated with PI-103 over the concentration range tested, did not achieve a GI50).

                      Tumor spheroid growth inhibition with 17-AAG and PI-103

                      For evaluation of the effects of molecularly targeted agents on three-dimensional tumor growth kinetics, 4-day-old spheroids (for example, U-87 MG) were treated with compounds for 72 h. Medium replenishment and imaging was performed as shown on the schematic protocol in Figure 6a. 17-AAG and PI-103 induced concentration-dependent growth inhibition (Figure 6b, d for 17-AAG and Figure 6e, g for PI-103).
                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig6_HTML.jpg
                      Figure 6

                      17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) and PI-103 concentration-dependent inhibition of tumor spheroid growth. (a) Schematic illustration of tumor spheroid growth kinetics and compound treatment procedures. Spheroids were initiated on day 0, treated with compound or vehicle on day 4, and 50% medium replenishment performed on days 7, 10 and 12. A Celigo cytometer was used for automated imaging and analysis. (b-g) Day 4 U-87 MG spheroids were treated with 17-AAG (heat shock protein 90 (HSP90) inhibitor) or PI-103 (phosphatidylinositol-3-kinase (PI3K)- mammalian target of rapamycin (mTOR) inhibitor) with 1:2 serial dilutions (final concentrations 0 to 4 μM for 17-AAG and 0 to 2 μM for PI-103). Control spheroids were treated with vehicle. Values are means ± SD (n = 6) and a representative of three separate experiments for each agent is shown. Student t test with Welch's correction was performed relative to the 14-day values: (b) vehicle controls vs 0.015 and 0.031 μM not significant; vs 0.062 μM P < 0.01; vs all higher concentrations P < 0.001; (e) vehicle controls vs 0.007 to 0.031 μM not significant; vs all higher concentrations P < 0.001. Screen prints of plates for (c) 17-AAG or (f) PI-103, corresponding to day 14 of the above graphs are also shown. Concentration response curves at day 14 for 17-AAG (d) and PI-103 (g) are shown. Values are means ± SD (n = 6).

                      This assay allows dynamic effects of compounds to be measured over time; a significant advantage compared to standard endpoint assays in two dimensions. Moreover, it can demonstrate whether a single administration of the agent is sufficient to inhibit spheroid growth or induce 'regression' as shown in Figure 6b. Note the excellent reproducibility of the spheroids on each plate across the six replicates/conditions (Figure 6c, f) and the Gaussian distribution of the spheroid volume that is maintained over the observation period, not only in controls but also in treated U-87 MG spheroids (Additional file 11). Tumor spheroid growth in this system is thus characterized by small standard deviations, which facilitate quantitative analysis and the ability to sensitively discern statistically significant differences between test and control conditions. Similar results of dose response inhibition on tumor spheroid growth were obtained with further cell lines, for example, KNS42 and LICR-LON-HN4, treated with PI-103 and 17-AAG, respectively (Additional file 12).

                      KNS42, LICR-LON-HN4 and U-87 MG generate tight spheroids, ideal for fully automated growth kinetic assays. With spheroids of looser morphology, or where agents cause dissociation of the three-dimensional structure, a Celigo cytometer still provides fully automated imaging but does not always provide accurate size determination. Images can then be imported into Image-Pro Analyzer software and manually manipulated for data analysis (data not shown). Alternatively, if no cytometer is available, images can be obtained using an inverted microscope and analyzed on Image-Pro Analyzer software. The results obtained using both methods are highly comparable; thus the latter is a perfectly acceptable (lower throughput) alternative. Two comparative examples are shown in Additional file 13 for U-87 MG and LICR-LON-HN4 spheroids treated with 17-AAG. Concentration-dependent inhibition trends are fully reproducible between the two imaging/analysis systems as demonstrated by a head-to-head comparison using LICR-LON-HN4 (Additional files 12 and 13).

                      HSP90 and PLCγ inhibitors prevent tumor dissemination on matrix protein

                      The tumor spheroid-based migration assay (Figure 4a) was adopted to mimic cell motility mediated by cell-substrate interactions. We previously reported that PLCγ1 is important in integrin-mediated cell migration [37]. To exemplify the power of the assay, we show here that an in-house PLCγ inhibitor (CCT130234) reduces the migration of both U-87 MG and MDA-MB-231 tumor cells at sub-GI50 concentrations (Figure 7a-c and Table 2).
                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig7_HTML.jpg
                      Figure 7

                      CCT130234 and 17- N -allylamino-17-demethoxygeldanamycin (17-AAG) concentration-dependent inhibition of tumor dissemination on matrix protein. (a-c) Day 4 U-87 MG and MDA-MB-231 P (parental variant) spheroids were placed on gelatin-coated plates and treated with the phospholipase C (PLC)γ inhibitor (CCT130234) over a range of concentrations. Controls were treated with vehicle. Images were captured at intervals (from t0 to 72 h) using an inverted microscope and analyzed with Image-Pro Analyzer software. Representative results of three separate experiments are shown for (a) U-87 MG and (b) MDA-MB-231 P. Values are means ± SD; (n = 12). Student t test with Welch's correction was performed relative to 72 h values: (a) vehicle control vs 2.5 to 10 μM P < 0.001; (b) vehicle control vs 2.5 to 10 μM P < 0.001. (c) Representative images for both cell lines at 72 h are shown. Scale bar: 500 μm. (d) U-87 MG, (e) KNS42 and (f) MDA-MB-231 P spheroids were treated with 17-AAG over a range of concentrations and the area of migration at 24 h post treatment quantified. Values are means ± SD; n = 6. Student t test with Welch's correction was performed: (d) vehicle control vs 0.1 to 2.5 μM P < 0.001; (e) vehicle control vs 0.2 μM **P < 0.01, vs 1 and 5 μM P < 0.001; (f) vehicle control vs 0.7 to 2.8 μM P < 0.001. A representative example of three separate experiments is shown for each cell line.

                      HSP90 is also involved in tumor cell migration through client proteins including c-MET, SRC and FAK [35]. The HSP90 inhibitor 17-AAG potently inhibited migration of U-87 MG, KNS42 and MDA-MB-231 cells in a concentration-dependent manner as early as 24 h (Figure 7d-f and Table 2). The fact that inhibitory effects are manifest at low concentrations and short time intervals is of particular importance, indicating selective effects on tumor cell migration at least partly independent of proliferation.

                      17-AAG inhibits three-dimensional tumor spheroid invasion into Matrigel

                      Another aspect of tumor progression is the ability of cells to invade basement membranes and connective tissue, enabling escape from the primary tumor and, in some cases, subsequent metastasis. U-87 MG glioma spheroids (representing a locally invasive tumor type) were embedded in Matrigel and treated with 17-AAG. Tumor cell invasion was monitored up to 72 h, although effects of the compound were apparent after just 24 h and invasion was inhibited at sub-GI50 concentrations (Figure 8a, b and Additional file 14a). A Celigo cytometer was used for a fully automated image analysis (Figure 8a) and representative images with the segmentation analysis around the invading cells are shown in Figure 8b at the 24 h timepoint. Additionally, similar results are obtained using the Celigo cytometer for automated imaging only, with the analysis performed on Image-Pro Analyzer software as an example of lower throughput (Additional file 14a). As indicated previously, a non-automated image capture and analysis method (microscopy and Image-Pro Analyzer software) can similarly be applied. This is illustrated by the inhibitory effects of 17-AAG on invasion of spheroids formed by highly malignant MDA-MB-231 M (metastatic variant) triple negative breast cancer cells (Additional file 14c).
                      http://static-content.springer.com/image/art%3A10.1186%2F1741-7007-10-29/MediaObjects/12915_2012_547_Fig8_HTML.jpg
                      Figure 8

                      17-N-Allylamino-17-demethoxygeldanamycin (17-AAG) mediated concentration-dependent inhibition of tumor spheroid invasion into Matrigel. (a, b) Day 4 U-87 MG spheroids were embedded into Matrigel for three-dimensional invasion. 17-AAG was used over a range of concentrations and control spheroids were treated with vehicle. Automated image analysis was carried out at intervals from t0 to 72 h on a Celigo cytometer using the Colony Counting Confluence application scanning 1/16 field of view/well. Invasion was normalized to t0. (a) A representative example of three separate experiments is shown. Values are means ± SD; n = 8. Student t test with Welch's correction was performed relative to 72 h values: vehicle control vs 0.1 to 2.5 μM P < 0.001. (b) Representative images of U-87 MG spheroid invasion obtained on a Celigo cytometer show the reproducibly sized spheroids at t0 and the typical segmentation around the invading cells with a clear inhibition by the 17-AAG at 24 h (also seen at concentrations below the concentration inhibiting cell viability by 50% (GI50) for this cell line (see Table 2)). Images of one field of view/well were cropped and magnified (20 ×) to allow visualization of the invasion. Scale bar: 500 μm.

                      Discussion

                      Building on the pioneering work of Friedrich et al. [26] and others, here we demonstrate a novel method for the rapid generation and quantitative analysis of tumor spheroid growth in HT format, with additional applications in further important aspects of the malignant phenotype. The assays can readily be established in any laboratory without specialized equipment and negate the need to purchase preformed spheroids, which may only be available for a limited number of cell lines. Although the quantitation is significantly enhanced by the use of automated cytometry, we have also deliberately exemplified its utility using standard microscopy to broaden its accessibility to the research community.

                      Recent advances in the development of three-dimensional cultures for cancer drug evaluation have focused mainly on methods that avoid cell surface adhesion and promote cell-cell attachment [12, 26, 52]. Most are based on cellular aggregation on agarose-coated flat-bottomed plates [26, 28], poly-Hema-coated round-bottomed or V-bottomed plates [52] or hanging drops [25]. Although able to generate reproducibly-sized spheroids, all such methods rely on time-consuming procedures or the need to transfer spheroids from delicate hanging drops to plates for further analysis. More recently, advances in microtechnologies have engineered plates for low binding of cells to the surface [30].

                      In pilot studies we compared different techniques for generating spheroids (bioreactor, agar-coated 96-well plates, poly-Hema-coated plates). We found that the ULA 96-well round-bottomed plate method is the least time consuming and generates the most reproducible spheroids. We have carried out a direct comparison with agar-coated plates and demonstrated that the tumor spheroids grown in ULA plates have equivalent growth rates, comparable gradients of proliferation and increased hypoxia in older spheroids but in general present a more compact and uniform structure. Also ULA plate-generated spheroids have the significant advantage that they are ideally suited to automated image analysis using a Celigo cytometer. Overall, the system (plus the additional simple extensions to key functional assays) represents an important advancement towards the routine use of three-dimensional cultures for preclinical oncology drug development.

                      HT three-dimensional growth assays must satisfy several key requirements: large scale, speed, simplicity, reproducibility and automation (both for set-up as well as readouts and data analysis). Here, we demonstrate that combining the use of ultra-low attachment round-bottomed plates with a Celigo cytometer, it is possible to utilize three-dimensional tumor spheroid assays in drug discovery projects in HT format. Building on this basic growth kinetic assay, we also successfully optimized de novo three-dimensional tumor spheroid-based functional assays in 96-well plates, for relatively HT formats: in situ three-dimensional tumor spheroid invasion into Matrigel, migration of cells from tumor spheroids on matrix proteins (also enabling detailed phenotypic analysis), and coculture of tumor spheroids with EBs representing tissue invasion with reciprocal angiogenesis.

                      In contrast to previously reported invasion assays [53, 54], our method avoids the need to move spheroids and allows true three-dimensional invasion rather than superficial interactions between spheroids placed on top of (or between) layers of matrix proteins. In the complementary assays of cell migration and tissue invasion/angiogenesis, preformed tumor spheroids are easily and quickly transferred onto matrix-coated wells or into coculture with EBs (uniformly generated using the same ULA plates as for spheroids), in a single step using multichannel pipettes. Our methods significantly accelerate and simplify the assays, but at the same time generate highly reproducible results. Furthermore, they combine real-time quantitative kinetic analyses with options for more detailed morphological and molecular investigations: for example, qualitative determinations of modes of cell motility; recovery of spheroids for genetic/phenotypic or pharmacodynamic analyses, target validation using cells in which genes of interest are genetically repressed or mutated.

                      The assays can easily be modified further according to specific requirements: migration/haptotaxis on different matrix proteins such as collagen, fibronectin, laminin, on endothelial cell monolayers, or (for glioblastomas) on recently described nanofiber scaffolds [15]: invasion into alternative matrixes (for example, collagen) or, to avoid animal tissue derivates, fully synthetic biopolymers; microenvironment-enriched spheroids incorporating endothelial cells, immune cells and/or stromal cells [10]. The current spheroid-EB coculture is designed to mimic xenograft tumor transplant systems (human tumors encountering mouse tissue/vasculature), the mainstay of preclinical drug evaluation studies, but human ESCs could be substituted to generate a fully human three-dimensional confrontation culture system.

                      In addition to optimization and streamlining of spheroid generation and a suite of functional assays, we have successfully automated imaging and quantitation of real-time spheroid growth and also invasion using a Celigo cytometer. We are currently developing further protocols for fully automated imaging and analysis of the migration and the coculture assays. These, together with the tumor spheroid growth kinetic and viability assays will allow a complete analytical package to bridge the gap between simple two-dimensional proliferation assays and in vivo studies. We are currently using these assays in a number of target validation and cancer drug discovery projects where our data suggest that they have the ability to reflect in vivo activity. Once fully validated for a wider range of agents and shown to have predictive value for therapeutic efficacy, we believe such assays will become a mainstay of the preclinical functional tumor assay portfolio and reduce the need for extensive testing in animal tumor models.

                      Conclusions

                      We provide a comprehensive suite of simple, reproducible three-dimensional tumor spheroid models that recapitulate in vitro some of the key hallmarks of cancer and that at the same time can provide a dynamic, automated, quantitative imaging and analysis compatible with high-throughput preclinical studies. We provide evidence that our methods have the potential to enhance target selection through rapid functional screening assays and the effective triaging of drug candidates prior to in vivo studies.

                      Methods

                      Cell lines and culture conditions

                      For the majority of our studies, four tumor cell lines representative of highly invasive cancers were selected: glioblastoma (U-87 MG, KNS42); oral squamous cell carcinoma (LICR-LON-HN4) and triple negative breast carcinoma (MDA-MB-231). Additional cell lines were included in spheroid formation trials to cover a wide range of tumor types.

                      Tumor cell lines (Table 1) were grown in tissue culture flasks under standard conditions (37°C, 5% CO2, 95% humidity). All media (Table 1) were as recommended by the supplier of the cells and were supplemented with 10% fetal calf serum (FCS), with the exception of the DLD-1 medium that was additionally supplemented with 1 × non-essential amino acids (NEAA). Media were routinely changed twice weekly. When subconfluent, cell monolayers were passaged using TrypLE Express Phenol Red, (Gibco, Life Technologies Ltd. Paysley, UK).

                      mES R1 cells were grown on mitomycin-C treated mouse embryonic fibroblast (MEF) feeder layers in ESC medium: Dulbecco's modified Eagle medium (DMEM) (4.5 g/l D-glucose; sodium pyruvate), supplemented with 15% FCS, 1 × penicillin, streptomycin and neomycin antibiotic mix (Gibco, Life Technologies Ltd. Paysley, UK), 100 μM β-mercaptoethanol (Sigma-Aldrich Company Ltd., Dorset, England), 1 × NEAA plus 1,000 U/ml leukemia inhibitor factor (LIF). Medium was changed 24 h after seeding (1.4 × 105 cells/ml, 5 ml/60 mm dish) and cells were passaged 2 to 3 days later. All media and NEAA were purchased from Gibco (Life Technologies Ltd. Paysley, UK), and FCS from Biosera.

                      Generation and analysis of tumor spheroids

                      For spheroid generation, 200 μl/well of cell suspensions at optimized densities (0.5 × 104 cells/ml for U-87 MG, KNS42 and LICR-LON-HN4; 1.5 × 104 for MDA-MB-231 P and M variants) were dispensed into ULA 96-well round-bottomed plates (Corning B.V. Life Sciences, Amsterdam, The Netherlands) using a multichannel pipette. Plates were incubated for 4 days at 37°C, 5% CO2, 95% humidity. Where indicated, optimal three-dimensional structures were achieved by addition of 2.5% Matrigel as previously described [52]. Fully automated image analysis of tumor spheroids was carried out on a Celigo cytometer (Cyntellect Inc, San Diego, CA, USA; http://​www.​cyntellect.​com/​content/​products/​celigo/​index.​html), which is equipped with a 4-megapixel CCD camera with an F-theta scan lens (1 μm/pixel, 0.25 NA, 3.5 ×). Images were acquired and analyzed by using the Colony Counting Embryoid Body application with the option to scan 1/16 field of view/well. The width of 1 field of view (FOV) is 975 pixels/2,057 μm and image file size is 0.41 MB. Further technical details of imaging parameters are shown in Additional file 15.

                      For the lower throughput method, images were captured using an inverted microscope (Olympus IX 70, (Olympus Microscopy, Southend-on-SeaEssex, UK) equipped with a CCD camera (QImaging, Surrey, BC, Canada and imported into Image-Pro Plus Analyzer software (Media Cybernetics, Inc., Bethesda, MD, USA; http://​www.​mediacy.​com/​index.​aspx?​page=​IPP) and by either using macros or manually, multiparametric analysis was performed. In both cases, the radius of each tumor spheroid was used to calculate the volume (μm3): V = 4/3 π r3.

                      For comparison with our system, U-87 MG cells were also used to generate spheroids using conventional methods as follows: (1) agar-coated 96-well flat-bottomed plates (BD Biosciences, Oxford, England) as previously described [26] (0.5 × 104 cells/ml as in the ULA 96-well round-bottomed plates); (2) poly-Hema-coated 24-well plates (2 × 105 cells/ml, 1 ml/well). A stock solution of 6 mg/ml poly-Hema (Sigma-Aldrich Company Ltd., Dorset, England) in 95% ethanol was prepared and diluted 1:10 in ethanol. A total of 100 μl/well was dispensed and left to dry before cell addition; (3) RCCS (105 cells/ml, 10 ml/disposable vessel).

                      In all cases, an inverted microscope was used for image analysis as described above.

                      Tumor spheroid growth kinetics and treatment with test compounds

                      Spheroids were generated as described above. Growth kinetics and inhibition assays were performed as previously reported [26] but with significant modifications. Briefly, spheroid size was measured up to 14 days after initiation. A 50% medium replenishment was performed on days 4, 7, 10 and 12 using a multichannel pipette. Image analysis was performed on a Celigo cytometer or by microscopy as described. Where indicated, day 4 tumor spheroids were treated with 17-AAG (Invivogen, San Diego, CA, USA), or PI-103 (Charnwood Molecular Ltd., Loughborough, UK). Control spheroids were treated with appropriate vehicle. Then, 72 h following compound addition, 50% medium replenishment was performed as described above. Responses were evaluated by spheroid volume measurements at regular intervals.

                      Tumor spheroid-based migration assay on matrix protein

                      Flat-bottomed, 96-well plates (Corning B.V. Life Sciences, Amsterdam, The Netherlands) were coated with 0.1% (v/v) gelatin (Sigma-Aldrich Company Ltd., Dorset, England) in sterile water for 1 h at 37°C. A total of 200 μl/well of culture medium supplemented with 2% (v/v) FCS was then added. For compound evaluation studies, medium contained 1.5 × the final concentration of 17-AAG or PLCγ inhibitor CCT130234, in a dilution series. Controls were treated with vehicle.

                      A total of 100 μl medium was removed from each well containing 4-day spheroids, and the remaining medium including the spheroids transferred into the prepared 'migration' plate using a multichannel pipette (final volume 300 μl). Spheroids were allowed to adhere and images were obtained at t0, 24, 48 and 72 h, using an inverted microscope as described. Effects of compounds were analyzed by measuring the area covered by migrating cells using Image-Pro Analyzer software to track the migration front. Data were normalized to the initial size of each spheroid at t0. For timelapse experiments, images were recorded every 15 minutes over a period of 70 h and videos edited using AVS Video Editor (Online Media Technologies Ltd., London, Uk).

                      Tumor spheroid-based Matrigel invasion assay

                      A total of 100 μl medium was removed from wells containing 4-day spheroids and 100 μl Matrigel was gently added. When Matrigel solidified, 100 μl of culture medium was added on top. For compound evaluation studies, 17-AAG or vehicle was added to both the Matrigel and the overlying medium. U-87 MG spheroids were treated on the day of assay initiation while MDA-MB-231 spheroids were pretreated for 24 h and during the assay. From t0 and at intervals up to 72 h, automated image analysis was carried out for U-87 MG on a Celigo cytometer, using the Cell Counting Confluence application. Due to the central location of the spheroid in each well, only 1/16 of the field of view needed to be imaged. The width for 1 FOV is 1,958 pixels/2,055 μm and image file size is 1.55 MB. A segmentation analysis around the invading cells was produced and invasion measured as the area covered by the invading cells (percentage confluence) in the scanned field of view. Analysis settings must be adjusted for each cell type in order to achieve an optimal image segmentation that also reflects the degree of invasion. Alternatively, images were imported and analyzed on Image-Pro Analyzer software as described above. Finally, to demonstrate that equivalent data can be generated in the absence of a sophisticated cytometer, microscopic imaging and analysis on Image-Pro Analyzer software was performed using MDA-MB-231 M cells. Further technical specifications for both imaging methods are provided in Additional file 15.

                      EB differentiation and tumor spheroid-EB confrontation culture

                      EB formation and cell differentiation was performed as described [50] with some modifications. R1 cells (1 to 5 × 103 cells/ml) in ESC medium containing 50 ng/ml vascular endothelial growth factor (VEGF) (Sigma-Aldrich Company Ltd., Dorset, England) were plated in ULA 96-well round-bottomed plates, 200 μl/well. A 50% medium refresh was performed daily from day 3 to day 14. Automated image analysis was performed using a Celigo cytometer as described and growth curves were generated.

                      For confrontation culture experiments [21], day 4 tumor spheroids and day 5 to day 7 EBs were used. Using a multichannel pipette, 100 μl of culture medium was removed from each well of the spheroid plate and replaced with 100 μl of ESC medium. This procedure was repeated three times, and after the last wash, remaining medium containing a single spheroid/well was transferred into the EB ULA plate to give a final volume of 200 μl/well, with one spheroid and one EB in each well. Confrontation cultures were incubated at 37°C in 5% CO2 for 60 h. To exemplify responses to a targeted agent, cocultures were treated with 17-AAG (5 μM) or with vehicle (control). For timelapse studies, videos were acquired on the Olympus microscope as described above. Images were recorded hourly over 65 h. Where indicated, GFP-transduced U-87 MG tumor spheroids were used and brightfield and fluorescence images of the confrontation cultures were obtained over 55 to 60 h on a Celigo cytometer, using the Expression Analysis application with the option to scan 1/16 field of view/well.

                      Determination of coefficient of variation (CV) and frequency distribution of tumor spheroid size

                      During assay optimization, the reproducibility of spheroid size was measured for U-87 MG, KNS42 and LICR-LON-HN4 cells by determining their volumes on day 4. The intraplate and interplate CV for each cell line was calculated in at least three separate experiments over three different batches of plates. The frequency of spheroid volumes was plotted to illustrate Gaussian distribution of the sample for U-87 MG spheroids on day 4 (untreated) and on day 14 (controls and compound treated) in a representative growth kinetic study.

                      Cell viability assay

                      Cell viability was measured using a CellTiter-Glo Luminescent Cell viability assay (Promega, Madison, WI, USA). In pilot studies to determine optimal incubation times, day 4 U-87 MG spheroids were incubated for 10, 30 and 60 minutes with CellTiter Glo reagents; all gave comparable results, hence a 10 minute incubation time was adopted for later studies. U-87 MG, KNS42, MDA-MB-231 and LICR-LON-HN4 spheroids were established as described. For cell monolayers (two-dimensional), cells were plated into 96-well black-sided flat-bottomed plates (Corning B.V. Life Sciences, Amsterdam, The Netherlands) at the following densities: 600 cells/well (U-87 MG, KNS42); 2,000 cells/well (MDA-MB-231) and 3,000 cells/well (LICR-LON-HN4). The outer wells of the plates were filled with phosphate-buffered saline (PBS) to reduce the effects of evaporation. Then, 4 days later, three-dimensional and two-dimensional cultures were treated with a range of concentrations of 17-AAG, PI-103, CCT130234 or appropriate vehicle. Cultures were incubated for 72 h and the CellTiter-Glo assay kit was used following the manufacturer's instructions. After 10 minutes of incubation with the CellTiter-Glo reagent, three-dimensional cultures were pipette mixed, aspirated with multichannel pipettes and transferred into black-sided, flat-bottomed plates (Corning B.V. Life Sciences, Amsterdam, The Netherlands) for luminescence measurement on a Synergy 2 SL Luminescence microplate reader (BioTek, Potton, UK) to generate GI50 values.

                      Immunohistochemistry

                      Tumor spheroids (TSs), EBs and TS-EB cocultures were processed for immunohistochemistry as follows. Three-dimensional structures were collected in V-bottomed 15 ml Falcon tubes and allowed to sediment. Supernatant was removed by gentle aspiration and pellets washed once with PBS. After repeated sedimentation, supernatant was removed and 4% paraformaldehyde (PFA) was added and left overnight. The next day, PFA was removed and, using a warmed p1000 pipette tip, 1 ml of liquid agarose (4% w/v in sterile water) was gently added to the three-dimensional structures that were then collected and transferred into Tissue-Tek®Cryomolds® (Sakura Finetek UK Ltd., Thatcham, UK). Solidified blocks were transferred into 50% ethanol for 1 h and then 80% ethanol before embedding in paraffin. Sections of 4 μm were cut using a semiautomated microtome HM 350 S (Microm International GmbH, Walldorf, Germany); the tissue sections were deparaffinized and rehydrated in water. Immunohistochemistry was performed as previously described [55] and sections were stained for Ki67 (monoclonal antibody, clone MIB1, Dako UK Ltd., Ely, UK), GLUT-1 (no. 07-1401, Millipore UK Ltd., London, UK) and CD34 (monoclonal antibody, clone MEC14.7, Abcam, Cambridge, UK). Slides were counterstained with hematoxylin and eosin and coverslipped with DPX mountant for microscopy (VWR Int., Lutterworth, UK).

                      Statistical analyses

                      The Student t test with Welch's correction was performed where indicated using Prism5 (Graphpad Software, La Jolla, CA, USA; http://​www.​graphpad.​com/​welcome.​htm). Values are expressed as means ± SD. P values ≤ 0.05 were considered statistically significant. For correlations between spheroid size (volume) and luminescent signal as well as for spheroid size and number of viable cells, Spearman correlation analysis was performed.

                      Declarations

                      Acknowledgements

                      We thank Somaieh Hedayat for additional spheroid data, Esther Díaz, María Miguel and Rocío López for technical assistance on IHC, Afshan McCarthy for R1 mESCs and Giovanna Balconi for advice on EB differentiation. We also thank Carol Box for critical comments on the manuscript. This work was funded by The National Centre for the Replacement, Refinement and Reduction of Animals in Research (G1000121 ID no. 94513), Cancer Research UK (grant number C309/A8274), and by Red Tematica de Investigación Cooperativa en Cancer (RD06/0020/1022). We acknowledge NHS funding to the NIHR Biomedical Research Centre. MM is supported by a postdoctoral research contract (FIS, Program 'Sara Borrell', Instituto de Salud Carlos III), Ministerio de Ciencia e Innovación, Spain.

                      Authors’ Affiliations

                      (1)
                      Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research
                      (2)
                      Laboratory of Pathology and Oncology, Research Unit, Fundación para la Investigación Biomedica de Hospital Universitario La Paz (FIBHULP), IdiPAZ
                      (3)
                      Department of Pathology, Hospital Universitario La Paz, Universidad Autónoma de Madrid, IdiPAZ

                      References

                      1. Hutchinson L, Kirk R: High drug attrition rates--where are we going wrong? Nat Rev Clin Oncol 2011, 8:189–190.PubMedView Article
                      2. Abbott A: Cell culture: biology's new dimension. Nature 2003, 424:870–872.PubMedView Article
                      3. Mazzoleni G, Di Lorenzo D, Steimberg N: Modelling tissues in 3D: the next future of pharmaco-toxicology and food research? Genes Nutr 2009, 4:13–22.PubMedView Article
                      4. Pampaloni F, Reynaud EG, Stelzer EH: The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007, 8:839–845.PubMedView Article
                      5. Ghosh S, Spagnoli GC, Martin I, Ploegert S, Demougin P, Heberer M, Reschner A: Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 2005, 204:522–531.PubMedView Article
                      6. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, Van Noorden CJ, Ylstra B, Leenstra S: The genomic profile of human malignant glioblastoma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008, 27:2091–2096.PubMedView Article
                      7. Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, Fry R, Samson LD, Tannenbaum SR, Griffith LG: A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 2005, 6:569–591.PubMedView Article
                      8. Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, Durchdewald M, Hess J, Barbus S, Campos B, Starzinski-Powitz A, Unterberg A, Reifenberger G, Lichter P, Herold-Mende C, Radlwimmer B: Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 2009, 15:6541–6550.PubMedView Article
                      9. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, Bissell MJ: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol 1997, 137:231–245.PubMedView Article
                      10. Friedrich J, Ebner R, Kunz-Schughart LA: Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge? Int J Radiat Biol 2007, 83:849–871.PubMedView Article
                      11. Fischbach C, Chen R, Matsumoto T, Schmelzle T, Brugge JS, Polverini PJ, Mooney DJ: Engineering tumors with 3D scaffolds. Nat Methods 2007, 4:855–860.PubMedView Article
                      12. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R: The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004, 9:273–285.PubMedView Article
                      13. Kim JB, Stein R, O'Hare MJ: Three-dimensional in vitro tissue culture models of breast cancer-a review. Breast Cancer Res Treat 2004, 85:281–291.PubMedView Article
                      14. Haycock JW: 3D cell culture: a review of current approaches and techniques. Methods Mol Biol 2011, 695:1–15.PubMedView Article
                      15. Agudelo-Garcia PA, De Jesus JK, Williams SP, Nowicki MO, Chiocca EA, Liyanarachchi S, Li PK, Lannutti JJ, Johnson JK, Lawler SE, Viapiano MS: Glioblastoma cell migration on three-dimensional nanofiber scaffolds is regulated by substrate topography and abolished by inhibition of STAT3 signaling. Neoplasia 2011, 13:831–840.PubMed
                      16. Sutherland RM, Sordat B, Bamat J, Gabbert H, Bourrat B, Mueller-Klieser W: Oxygenation and differentiation in multicellular spheroids of human colon carcinoma. Cancer Res 1986, 46:5320–5329.PubMed
                      17. Hirschhaeuser F, Menne H, Dittfeld C, West J, Mueller-Klieser W, Kunz-Schughart LA: Multicellular tumor spheroids: an underestimated tool is catching up again. J Biotechnol 2010, 148:3–15.PubMedView Article
                      18. Sutherland RM, McCredie JA, Inch WR: Growth of multicell spheroids in tissue culture as a model of nodular carcinomas. J Natl Cancer Inst 1971, 46:113–120.PubMed
                      19. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB: Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821–5828.PubMed
                      20. Deisboeck TS, Berens ME, Kansal AR, Torquato S, Stemmer-Rachamimov AO, Chiocca EA: Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model. Cell Prolif 2001, 34:115–134.PubMedView Article
                      21. Wartenberg M, Donmez F, Ling FC, Acker H, Hescheler J, Sauer H: Tumor-induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. FASEB J 2001, 15:995–1005.PubMedView Article
                      22. Unsworth BR, Lelkes PI: Growing tissues in microgravity. Nat Med 1998, 4:901–907.PubMedView Article
                      23. Ivascu A, Kubbies M: Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol 2007, 31:1403–1413.PubMed
                      24. Xiang X, Phung Y, Feng M, Nagashima K, Zhang J, Broaddus VC, Hassan R, Fitzgerald D, Ho M: The development and characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy. PLoS One 2011, 6:e14640.PubMedView Article
                      25. Del Duca D, Werbowetski T, Del Maestro RF: Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion. J Neurooncol 2004, 67:295–303.PubMedView Article
                      26. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA: Spheroid-based drug screen: considerations and practical approach. Nat Protoc 2009, 4:309–324.PubMedView Article
                      27. Weiswald LB, Guinebretiere JM, Richon S, Bellet D, Saubamea B, Dangles-Marie V: In situ protein expression in tumour spheres: development of an immunostaining protocol for confocal microscopy. BMC Cancer 2010, 10:106.PubMedView Article
                      28. Li Q, Chen C, Kapadia A, Zhou Q, Harper MK, Schaack J, LaBarbera DV: 3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J Biomol Screen 2011, 16:141–154.PubMedView Article
                      29. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L: Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008, 10:R10.PubMedView Article
                      30. Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009, 27:1006–1020.PubMedView Article
                      31. Lee GY, Kenny PA, Lee EH, Bissell MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007, 4:359–365.PubMedView Article
                      32. Matsuda Y, Ishiwata T, Kawamoto Y, Kawahara K, Peng WX, Yamamoto T, Naito Z: Morphological and cytoskeletal changes of pancreatic cancer cells in three-dimensional spheroidal culture. Med Mol Morphol 2010, 43:211–217.PubMedView Article
                      33. Hardelauf H, Frimat JP, Stewart JD, Schormann W, Chiang YY, Lampen P, Franzke J, Hengstler JG, Cadenas C, Kunz-Schughart LA, West J: Microarrays for the scalable production of metabolically relevant tumour spheroids: a tool for modulating chemosensitivity traits. Lab Chip 2011, 11:419–428.PubMedView Article
                      34. Howes AL, Chiang GG, Lang ES, Ho CB, Powis G, Vuori K, Abraham RT: The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol Cancer Ther 2007, 6:2505–2514.PubMedView Article
                      35. Moser C, Lang SA, Kainz S, Gaumann A, Fichtner-Feigl S, Koehl GE, Schlitt HJ, Geissler EK, Stoeltzing O: Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol Cancer Ther 2007, 6:2868–2878.PubMedView Article
                      36. McCready J, Sims JD, Chan D, Jay DG: Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer 2010, 10:294.PubMedView Article
                      37. Jones NP, Peak J, Brader S, Eccles SA, Katan M: PLCgamma1 is essential for early events in integrin signalling required for cell motility. J Cell Sci 2005, 118:2695–2706.PubMedView Article
                      38. Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, Hunter R, Stratford I, West C: Glucose transporter Glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001, 7:928–934.PubMed
                      39. Ilina O, Friedl P: Mechanisms of collective cell migration at a glance. J Cell Sci 2009, 122:3203–3208.PubMedView Article
                      40. Rorth P: Collective cell migration. Annu Rev Cell Dev Biol 2009, 25:407–429.PubMedView Article
                      41. Vajkoczy P, Farhadi M, Gaumann A, Heidenreich R, Erber R, Wunder A, Tonn JC, Menger MD, Breier G: Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002, 109:777–785.PubMed
                      42. Vajkoczy P, Menger MD, Goldbrunner R, Ge S, Fong TA, Vollmar B, Schilling L, Ullrich A, Hirth KP, Tonn JC, Schmiedek P, Rempel SA: Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. Int J Cancer 2000, 87:261–268.PubMedView Article
                      43. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, Kiessling F, Eichelsbacher U, Essig M, Read TA, Erber R, Ullrich A: Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 2006, 103:5799–5804.PubMedView Article
                      44. Deryugina EI, Bourdon MA: Tenascin mediates human glioblastoma cell migration and modulates cell migration on fibronectin. J Cell Sci 1996, 109:643–652.PubMed
                      45. Friedl P: Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 2004, 16:14–23.PubMedView Article
                      46. Sanz-Moreno V, Marshall CJ: The plasticity of cytoskeletal dynamics underlying neoplastic cell migration. Curr Opin Cell Biol 2010, 22:690–696.PubMedView Article
                      47. Stylli SS, Kaye AH, Lock P: Invadopodia: At the cutting edge of tumour invasion. J Clin Neurosci 2008, 15:725–737.PubMedView Article
                      48. Ayala I, Baldassarre M, Caldieri G, Buccione R: Invadopodia: a guided tour. Eur J Cell Biol 2006, 85:159–164.PubMedView Article
                      49. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A: The history of the angiogenic switch concept. Leukemia 2007, 21:44–52.PubMedView Article
                      50. Balconi G, Spagnuolo R, Dejana E: Development of endothelial cell lines from embryonic stem cells: A tool for studying genetically manipulated endothelial cells in vitro. Arterioscler Thromb Vasc Biol 2000, 20:1443–1451.PubMedView Article
                      51. Minchinton AI, Tannock IF: Drug penetration in solid tumours. Nat Rev Cancer 2006, 6:583–592.PubMedView Article
                      52. Ivascu A, Kubbies M: Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis. J Biomol Screen 2006, 11:922–932.PubMedView Article
                      53. Sodek KL, Ringuette MJ, Brown TJ: Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 2009, 124:2060–2070.PubMedView Article
                      54. Harma V, Virtanen J, Makela R, Happonen A, Mpindi JP, Knuuttila M, Kohonen P, Lotjonen J, Kallioniemi O, Nees M: A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS One 2010, 5:e10431.PubMedView Article
                      55. Mendiola M, Barriuso J, Marino-Enriquez A, Redondo A, Dominguez-Caceres A, Hernandez-Cortes G, Perez-Fernandez E, Sanchez-Navarro I, Vara JA, Suarez A, Espinosa E, González-Barón M, Palacios J, Hardisson D: Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum Pathol 2009, 40:631–638.PubMedView Article
                      56. Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G, Workman P, Sheer D, Reis RM, Pearson AD, Hargrave D, Jones C: Molecular and phenotypic characterisation of paediatric glioblastoma cell lines as models for preclinical drug development. PLoS One 2009, 4:e5209.PubMedView Article
                      57. O-charoenrat P, Rhys-Evans P, Eccles S: Characterization of ten newly-derived human head and neck squamous carcinoma cell lines with special reference to c-erbB proto-oncogene expression. Anticancer Res 2001, 21:1953–1963.PubMed
                      58. Easty DM, Easty GC, Carter RL, Monaghan P, Butler LJ: Ten human carcinoma cell lines derived from squamous carcinomas of the head and neck. Br J Cancer 1981, 43:772–785.PubMedView Article

                      Copyright

                      © Vinci et al; licensee BioMed Central Ltd. 2012

                      Advertisement